SiNtx Technologies, Inc. SINT 深 滬
交易中 10-27 09:45:29 美东时间
3.82
+0.070
+1.87%
華盛通- 最 高3.82
- 今 開3.78
- 成交量 1.20万股
- 最 低 3.75
- 昨 收 3.75
- 總市值 1369.81万
- 52周最高 8.5961
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.71
- 委 比 -63.22%
- 總股本 358.59万
- 歷史最高 209400.00
- 量 比 3.26
- 振 幅 1.87%
- 歷史最低 1.71
- 每 手 1
- 風險率 0.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System
SINTX Technologies announced FDA clearance for its SINAPTIC® Foot & Ankle Osteotomy Wedge System, enabling entry into the $5.4 billion U.S. foot and ankle device market. The system combines silicon nitride biomaterial with surgeon-informed designs, offering advantages like osseointegration, bacteriostasis, hydrophilicity, and superior imaging visibility. SINTX plans a U.S. launch in Q1 2026, leveraging domestic manufacturing to drive growth and e...
10-20 11:00
UPDATE: SINTX Strengthens Infection-Prevention Portfolio with Newly Allowed U.S. Patent Covering $30 Billion Antipathogenic Addressable Market
<p>SINTX Technologies has been granted a U.S. patent for its antipathogenic fabric technology's method claims, enhancing its IP portfolio to protect both material composition and manufacturing processes. This dual coverage strengthens competitive advantage and expands licensing opportunities across medical textiles, filtration, and PPE. CEO Eric Olson highlighted the milestone as reinforcing the company's leadership in infection-resistant materia...
10-16 11:00
SINTX Technologies Expands Patent Protections for Antipathogenic Fabrics, Strengthening Biomedical IP Portfolio
SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics innovator specializing in biomedical applications of silicon nitride (Si₃N₄), today announced that the United States Patent and
10-14 19:16
SINTX Technologies Strengthens IP Portfolio with New U.S. Patent Notice of Allowance Covering Antipathogenic Fabrics
SINTX Technologies announced the allowance of a method patent for its antipathogenic fabric technology, reinforcing its IP portfolio in a $30B infection-prevention market. This patent complements its earlier composition patent, providing dual protection for both materials and manufacturing processes, enhancing licensing and commercialization opportunities across medical textiles, filtration, and PPE. The dual-patent estate strengthens SINTX's com...
10-14 11:00
Sintx Technologies Announces At The Market Offering
Sintx Technologies ( ($SINT) ) has issued an announcement. On October 3, 2025, ...
10-04 05:28
Sintercom India Limited Concludes 18th AGM with E-Voting Results
The latest update is out from Sintercom India Ltd. ( ($IN:SINTERCOM) ). Sinterc...
09-27 05:10
Sintercom India Re-appoints Dara J Kalyaniwala as Independent Director
The latest update is out from Sintercom India Ltd. ( ($IN:SINTERCOM) ). Sinterc...
09-27 05:09
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Ascendiant Capital Maintains Buy on SINTX Technologies, Lowers Price Target to $25
Ascendiant Capital analyst Edward Woo maintains SINTX Technologies (NASDAQ:SINT) with a Buy and lowers the price target from $28 to $25.
09-22 17:43
